Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.

Abstract: The present invention provides scanning mechanisms for imaging probes using for imaging mammalian tissues and structures using high resolution imaging, including high frequency ultrasound and/or optical coherence tomography. The imaging probes include adjustable rotational drive mechanism for imparting rotational motion to an imaging assembly containing either optical or ultrasound transducers which emit energy into the surrounding area. The imaging assembly includes a scanning mechanism having including a movable member configured to deliver the energy beam along a path out of said elongate hollow shaft at a variable angle with respect to said longitudinal axis to give forward and side viewing capability of the imaging assembly. The movable member is mounted in such a way that the variable angle is a function of the angular velocity of the imaging assembly.

Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Abstract: The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.

Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.

Abstract: The present invention provides an imaging probe for imaging mammalian tissues and structures using high resolution imaging, including ultrasound and optical coherence tomography. The imaging probe uses electrostatic discharge for actuating a metalized cantilever which holds the end portion of imaging assembly which emits energy in the imaging probe device by holding the cantilever at a potential such that it is neither grounded or charged such that the only electrical path to ground is through a dissipative polymer forming part of the device which is enveloped by a wire or coil held at ground potential. A high voltage electrode attracts the metalized cantilever and the dissipative polymer is used to connect to the cantilever to ground causing the cantilever to move about thereby scanning the region in front of the probe.

Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Abstract: The present invention provides an imaging probe for imaging mammalian tissues and structures using high resolution imaging, including high frequency ultrasound and optical coherence tomography. The imaging probes structures using high resolution imaging use combined high frequency ultrasound (IVUS) and optical imaging methods such as optical coherence tomography (OCT) and to accurate co-registering of images obtained from ultrasound image signals and optical image, signals during scanning a region of interest.

Abstract: The present invention provides minimally invasive imaging probe having an optical encoder integrated therewith for accurately measuring or estimating the rotational velocity near the distal end of the medical device, such as an imaging probe which undergoes rotational movement during scanning of surrounding tissue in bodily lumens and cavities.

Abstract: The present invention provides scanning mechanisms for imaging probes using for imaging mammalian tissues and structures using high resolution imaging, including high frequency ultrasound and/or optical coherence tomography. The imaging probes include adjustable rotational drive mechanism for imparting rotational motion to an imaging assembly containing either optical or ultrasound transducers which emit energy into the surrounding area. The imaging assembly includes a scanning mechanism having including a movable member configured to deliver the energy beam along a path out of said elongate hollow shaft at a variable angle with respect to said longitudinal axis to give forward and side viewing capability of the imaging assembly. The movable member is mounted in such a way that the variable angle is a function of the angular velocity of the imaging assembly.

Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.

Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Abstract: The present invention relates to novel exendin agonist compounds useful in treatment of Type I and II diabetes, and useful in lowering plasma glucose levels, reducing body weight, and delaying and/or slowing gastric emptying.

Abstract: The present invention relates to a process for preparing a solid laundry detergent composition comprising: (a) anionic detersive surfactant; (b) from 0% to less than 5%, by weight of the composition, of zeolite builder; (c) from 0% to less than 5%, by weight of the composition, of phosphate builder; and (d) optionally, from 0% to less than 5%, by weight of the composition, of silicate salt; wherein the process comprises the steps of: (i) preparing an aqueous mixture comprising an anionic detersive surfactant; (ii) subjecting the aqueous mixture to a first drying step having a mean drying-duration time of less than 60 seconds and a mean drying rate of from 0.005 to 0.030 kg of water per kg of aqueous mixture per second to form a partially dried aqueous mixture; and (iii) subjecting the partially dried aqueous mixture to a second drying step having a mean drying-duration time of at least 10 seconds and a mean drying rate of from 0.0005 to less than 0.

Abstract: The present invention relates to a solid laundry detergent composition in particulate form, comprising: (a) anionic detersive surfactant; (b) a solid carrier material having: (i) a total pore volume of greater than 0.3 ml/g; (ii) an average pore diameter of greater than 3 micrometers; and (iii) a surface area of less than 1.0 m2/g; (c) from 0% to less than 5%, by weight of the composition, of zeolite builder; (d) from 0% to less than 5%, by weight of the composition, of phosphate builder and (e) optionally, from 0% to less than 5%, by weight of the composition, of silicate salt; wherein at least part of the anionic detersive surfactant and at least part of the solid carrier material are in the form of a co-particulate admix.

Abstract: Novel exendin peptide compounds are provided.

Abstract: A reciprocating saw is provided which includes a drive shaft having a saw blade clamping means at an end thereof for securing a saw blade thereto in use, and drive means for driving reciprocation of the drive shaft and thus an attached saw blade relative to a body portion of the saw in use. The saw further includes saw blade support means for engaging a surface of the saw blade in use for supporting the same. The saw blade support means is pivotally mounted to a part of the body portion of the saw or to a substantially stationary bearing associated with the drive shaft to allow passive movement of the blade support means with the drive shaft and/or saw blade in use.

Abstract: Provided are methods for lowering plasma lipid in an individual in need of or desirous of lowering plasma lipid by administering an amount of an exendin or an exendin agonist analog effective to lower plasma lipid.